Moneycontrol PRO
HomeNewsSunpharmaceuticalindustries
Jump to
  • Buy Sun Pharma; target of Rs 1635: Motilal Oswal

    Motilal Oswal is bullish on Sun Pharma recommended buy rating on the stock with a target price of Rs 1635 in its research report dated January 31, 2024.

  • Hold Sun Pharma; target of Rs 1400: ICICI Securities

    ICICI Securities recommended hold rating on Sun Pharma with a target price of Rs 1400 in its research report dated January 31, 2024.

  • Buy Sun Pharmaceutical Industries; target of Rs 1640: Prabhudas Lilladher

    Prabhudas Lilladher is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1640 in its research report dated February 01, 2024.

  • Buy Sun Pharmaceutical Industries; target of Rs 1400 Sharekhan

    Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1400 in its research report dated December 08, 2023.

  • Buy Sun Pharmaceutical Industries; target of Rs 1280: Prabhudas Lilladher

    Prabhudas Lilladher is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1280 in its research report dated November 02, 2023.

  • Buy Sun Pharmaceutical Industries; target of Rs 1265: Prabhudas Lilladher

    Prabhudas Lilladher is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1265 in its research report dated August 03, 2023.

  • Buy Sun Pharmaceutical Industries; target of Rs 1300: Sharekhan

    Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1300 in its research report dated August 03, 2023.

  • Buy Sun Pharma; target of Rs 1310: Motilal Oswal

    Motilal Oswal is bullish on Sun Pharma recommended buy rating on the stock with a target price of Rs 1310 in its research report dated August 03, 2023.

  • Sun Pharma: Steady growth, but higher valuation

    Higher R&D expense, moderation of Revlimid opportunity, higher operational expenses and increased competitive intensity would weigh on the company in the near term. We remain on the sidelines

  • Buy Sun Pharmaceutical Industries; target of Rs 1172: KR Choksey

    KR Choksey is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1172 in its research report dated May 31, 2023.

  • Buy Sun Pharmaceutical Industries; target of Rs 1123: Sharekhan

    Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1123 in its research report dated May 29, 2023.

  • Buy Sun Pharmaceutical Industries; target of Rs 1140: Prabhudas Lilladher

    Prabhudas Lilladher is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1140 in its research report dated May 28, 2023.

  • Buy Sun Pharma; target of Rs 1160: Motilal Oswal

    Motilal Oswal is bullish on Sun Pharma recommended buy rating on the stock with a target price of Rs 1160 in its research report dated May 27, 2023.

  • Sun Pharma: Stretched valuation a sticking point, what else to watch out for?

    Elevated promotional/travel expenses and increased competitive intensity would weigh on margins

  • Buy Sun Pharmaceutical Industries; target of Rs 1175: Prabhudas Lilladher

    Prabhudas Lilladher is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1175 in its research report dated February 01, 2023.

  • Buy Sun Pharmaceuticals Industries; target of Rs 1300: Sharekhan

    Sharekhan is bullish on Sun Pharmaceuticals Industries has recommended buy rating on the stock with a target price of Rs 1300 in its research report dated January 31, 2023.

  • Buy Sun Pharmaceutical Industries; target of Rs 1210: ICICI Direct

    ICICI Direct is bullish on Sun Pharmaceutical Industries recommended buy rating on the stock with a target price of Rs 1210 in its research report dated February 01, 2023.

  • Buy Sun Pharmaceuticals Industries; target of Rs 1300: Sharekhan

    Sharekhan is bullish on Sun Pharmaceuticals Industries has recommended buy rating on the stock with a target price of Rs 1300 in its research report dated December 07, 2022.

  • Buy Sun Pharmaceutical Industries; target of Rs 1300: Sharekhan

    Sharekhan is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1300 in its research report dated November 02, 2022.

  • Buy Sun Pharmaceutical Industries; target of Rs 1175: Prabhudas Lilladher

    Prabhudas Lilladher is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1175 in its research report dated November 02, 2022.

  • Sun Pharma: Slowdown in speciality clinical trials needs to be watched

    For FY23, we continue with the estimates that the top line of Sun Pharma would grow in a high single digit only

  • Buy Sun Pharmaceuticals Industries; target of Rs 1130: Sharekhan

    Sharekhan is bullish on Sun Pharmaceuticals Industries has recommended buy rating on the stock with a target price of Rs 1130 in its research report dated July 29, 2022.

  • Buy Sun Pharmaceutical Industries; target of Rs 1070: Prabhudas Lilladher

    Prabhudas Lilladher is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1070 in its research report dated July 31, 2022.

  • Buy Sun Pharma; target of Rs 1100: Motilal Oswal

    Motilal Oswal is bullish on Sun Pharma recommended buy rating on the stock with a target price of Rs 1100 in its research report dated July 30, 2022.

  • Buy Sun Pharmaceutical Industries; target of Rs 1125: ICICI Direct

    ICICI Direct is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1125 in its research report dated July 30, 2022.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347